temozolomide has been researched along with Cognition Disorders in 11 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 7.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 7.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 5.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy." | 3.81 | EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. ( Benderitter, M; Bernier, MO; Brochet, B; Delattre, JY; Douzane, H; Durand, T; Feuvret, L; Hoang-Xuan, K; Jacob, S; Lebouil, L; Leclercq, D; Lestaevel, P; Milliat, F; Noël, G; Psimaras, D; Rahimian, A; Ricard, D; Tamarat, R; Vayatis, N, 2015) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 3.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide." | 3.80 | Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study. ( Bosma, I; Buter, J; de Groot, M; Douw, L; Froklage, FE; Heimans, JJ; Klein, M; Lagerwaard, FJ; Oosterbaan, LJ; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Uitdehaag, BM, 2014) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 3.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 1.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Sixty-eight patients with brain tumors were studied (60% high-grade glioma)." | 1.36 | Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials. ( Anderson, SK; Brown, PD; Cerhan, JH; Lageman, SK; Locke, DE; Wu, W, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Habets, EJ | 1 |
| Taphoorn, MJ | 1 |
| Nederend, S | 1 |
| Klein, M | 3 |
| Delgadillo, D | 1 |
| Hoang-Xuan, K | 2 |
| Bottomley, A | 1 |
| Allgeier, A | 1 |
| Seute, T | 1 |
| Gijtenbeek, AM | 1 |
| de Gans, J | 1 |
| Enting, RH | 1 |
| Tijssen, CC | 1 |
| van den Bent, MJ | 1 |
| Reijneveld, JC | 3 |
| Saito, K | 1 |
| Mukasa, A | 1 |
| Narita, Y | 1 |
| Tabei, Y | 1 |
| Shinoura, N | 1 |
| Shibui, S | 1 |
| Saito, N | 1 |
| Froklage, FE | 1 |
| Oosterbaan, LJ | 1 |
| Sizoo, EM | 1 |
| de Groot, M | 1 |
| Bosma, I | 2 |
| Sanchez, E | 1 |
| Douw, L | 1 |
| Heimans, JJ | 2 |
| Lagerwaard, FJ | 1 |
| Buter, J | 2 |
| Uitdehaag, BM | 1 |
| Postma, TJ | 2 |
| Durand, T | 1 |
| Jacob, S | 1 |
| Lebouil, L | 1 |
| Douzane, H | 1 |
| Lestaevel, P | 1 |
| Rahimian, A | 1 |
| Psimaras, D | 1 |
| Feuvret, L | 1 |
| Leclercq, D | 1 |
| Brochet, B | 1 |
| Tamarat, R | 1 |
| Milliat, F | 1 |
| Benderitter, M | 1 |
| Vayatis, N | 1 |
| Noël, G | 1 |
| Delattre, JY | 1 |
| Ricard, D | 1 |
| Bernier, MO | 1 |
| Lorimer, CF | 1 |
| Saran, F | 1 |
| Chalmers, AJ | 1 |
| Brock, J | 1 |
| Peddi, P | 1 |
| Ajit, NE | 1 |
| Burton, GV | 1 |
| El-Osta, H | 1 |
| Lageman, SK | 1 |
| Cerhan, JH | 1 |
| Locke, DE | 1 |
| Anderson, SK | 1 |
| Wu, W | 1 |
| Brown, PD | 1 |
| Shibamoto, Y | 1 |
| Sugie, C | 1 |
| Iwata, H | 1 |
| Hilverda, K | 1 |
| Peter Vandertop, W | 1 |
| Slotman, BJ | 1 |
| Brown, P | 1 |
| Buckner, J | 1 |
| Macdonald, DR | 1 |
| Kiebert, G | 1 |
| Prados, M | 1 |
| Yung, A | 1 |
| Olson, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EPIBRAINRAD : Study of Neurological Complication After Radiotherapy for Glioblastoma High Grade[NCT02544178] | 200 participants (Anticipated) | Observational | 2015-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for temozolomide and Cognition Disorders
| Article | Year |
|---|---|
Radiotherapy for metastatic brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Cra | 2009 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
9 other studies available for temozolomide and Cognition Disorders
| Article | Year |
|---|---|
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.
Topics: Aged; Astrocytoma; Brain Neoplasms; Cognition Disorders; Cohort Studies; Dacarbazine; DNA Modificati | 2014 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Atrophy; Brain Neoplasms; Cerebral Corte | 2014 |
EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cognition Disorde | 2015 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neop | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Disorders; Dac | 2010 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Di | 2010 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |